Department of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton and Hamilton Center for Kidney Research, Hamilton, Ontario L8N 4A6, Canada.
Departments of Biology and Pathology, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
J Biol Chem. 2018 May 11;293(19):7329-7343. doi: 10.1074/jbc.RA117.001049. Epub 2018 Mar 28.
The proprotein convertase subtilisin/kexin type-9 (PCSK9) plays a central role in cardiovascular disease (CVD) by degrading hepatic low-density lipoprotein receptor (LDLR). As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD. The retention of misfolded protein in the ER can cause ER stress and activate the unfolded protein response (UPR). In this study, we investigated whether a variety of LOF PCSK9 variants that are retained in the ER can cause ER stress and hepatic cytotoxicity. Although overexpression of these PCSK9 variants caused an accumulation in the ER of hepatocytes, UPR activation or apoptosis was not observed. Furthermore, ER retention of endogenous PCSK9 via splice switching also failed to induce the UPR. Consistent with these studies, overexpression of PCSK9 in the livers of mice had no impact on UPR activation. To elucidate the cellular mechanism to explain these surprising findings, we observed that the 94-kDa glucose-regulated protein (GRP94) sequesters PCSK9 away from the 78-kDa glucose-regulated protein (GRP78), the major activator of the UPR. As a result, GRP94 knockdown increased the stability of GRP78-PCSK9 complex and resulted in UPR activation following overexpression of ER-retained PCSK9 variants relative to WT secreted controls. Given that overexpression of these LOF PCSK9 variants does not cause UPR activation under normal homeostatic conditions, therapeutic strategies aimed at blocking the autocatalytic cleavage of PCSK9 in the ER represent a viable strategy for reducing circulating PCSK9.
前蛋白转化酶枯草溶菌素/胰凝乳蛋白酶 9(PCSK9)通过降解肝脏低密度脂蛋白受体(LDLR)在心血管疾病(CVD)中发挥核心作用。因此,无法从内质网(ER)中逸出的功能丧失(LOF)PCSK9 变体增加了肝脏 LDLR 水平,降低了患 CVD 的风险。错误折叠的蛋白质在 ER 中的滞留会引起 ER 应激并激活未折叠蛋白反应(UPR)。在这项研究中,我们研究了各种滞留在 ER 中的 LOF PCSK9 变体是否会引起 ER 应激和肝毒性。尽管这些 PCSK9 变体的过表达导致肝细胞内质网中积累,但未观察到 UPR 激活或细胞凋亡。此外,通过剪接切换将内源性 PCSK9 保留在 ER 中也未能诱导 UPR。与这些研究一致,在小鼠肝脏中过表达 PCSK9 对 UPR 激活没有影响。为了阐明解释这些令人惊讶的发现的细胞机制,我们观察到 94kDa 葡萄糖调节蛋白(GRP94)将 PCSK9 与主要 UPR 激活剂 78kDa 葡萄糖调节蛋白(GRP78)隔离。结果,GRP94 敲低增加了 GRP78-PCSK9 复合物的稳定性,并且与 WT 分泌对照相比,过表达 ER 保留的 PCSK9 变体后会导致 UPR 激活。鉴于在正常的体内平衡条件下,这些 LOF PCSK9 变体的过表达不会引起 UPR 激活,因此旨在阻止 PCSK9 在 ER 中自动切割的治疗策略代表了降低循环 PCSK9 的可行策略。